ASCO GI 2021 | TAGS: impact of prior therapies on outcomes with trifluridine/tipiracil

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the result of a post-hoc analysis evaluating the impact of prior treatment on the outcomes of third-line chemotherapy in patients enrolled in the Phase III TAGS trial investigating trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).